TrialPath

Find a study

Match me to a study

45 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

39 studies on the map

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis — Sun Valley Arthritis Center /ID# 278331, PeoriaA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaRA-PRO PRAGMATIC TRIAL — East Alabama Arthritis Center PC, AuburnA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. — Artiva Investigational Site Tuscaloosa, TuscaloosaA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — GSK Investigational Site, ChandlerA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis — Research Site, GlendaleA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH — University of California San Diego, La JollaA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — HonorHealth Research and Innovation Institute, ScottsdaleA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) — SunValley Arthritis Center Ltd., PeoriaA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) — Arizona Arthritis & Rheumatology Associates, GilbertA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) — Nkarta Investigational Site, OrangeA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamA Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis — Nouvelle Clinical Research LLC, Cutler BayA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerQuantifying Hepatic Mitochondrial Fluxes in Humans — Texas Diabetes Institute - University Health System, San AntonioDigoxin In NASH (CODIN) — Yale New Haven Health, New HavenDynamic Treatment Regiments for Glucocorticoid Tapering — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborLow-Dose Pioglitazone in Patients With NASH (AIM 2) — University of Florida, GainesvilleEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraImpact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) — Cincinnati Children's Hospital Medical Center, CincinnatiMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — Harry S. Truman Memorial, Columbia, MO, ColumbiaMilk Thistle Clinical Trial in Pediatric NAFLD — University Hospitals Cleveland Medical Center, ClevelandRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT — UPMC Children's Hospital of Pittsburgh, PittsburghTreatment of Rheumatoid Arthritis With DMARDs: Predictors of Response — University of Nebraska Medical Center, OmahaAn Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis — DM Clinical Research, Tomball